BrainsWay Ltd. (BWAY)

Market Cap	626.56M +231.2%
Revenue (ttm)	52.23M +27.3%
Net Income	7.63M +161.3%
EPS	0.18 +225.1%
Shares Out	36.66M
PE Ratio	82.09
Forward PE	50.95
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85,371
Open	15.50
Previous Close	15.33
Day's Range	15.21 - 16.04
52-Week Range	3.92 - 16.24
Beta	0.31
Analysts	Strong Buy
Price Target	13.25 (-16.19%)
Earnings Date	May 12, 2026

About BWAY

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves do...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 17, 2019
• Employees: 120
• Stock Exchange: NASDAQ
• Ticker Symbol: BWAY
• Website: https://www.brainsway.com

Financial Performance

In 2025, BrainsWay's revenue was $52.23 million, an increase of 27.33% compared to the previous year's $41.02 million. Earnings were $7.63 million, an increase of 161.31%.

Analyst Summary

According to 2 analysts, the average rating for BWAY stock is "Strong Buy." The 12-month stock price target is $13.25, which is a decrease of -16.19% from the latest price.

Price Target

$13.25

(-16.19% downside)

Analyst Consensus: Strong Buy